Novartis announced positive data from a mid-stage study on iptacopan (LNP023), a first-in-class, oral, targeted factor B inhibitor, at the 58th ERA-EDTA Congress. AG ( NVS Quick Quote NVS - Free Report)
Patients (n=112) with immunoglobulin nephropathy (IgAN) were randomized to placebo or different doses of iptacopan in the phase II study (NCT03373461).
Iptacopan met its primary endpoint for rare kidney disease IgA nephropathy (IgAN). The candidate reduced protein in the urine (proteinuria), an increasingly recognized surrogate marker correlating with progression to kidney failure, and showed immense promise in stabilizing kidney function among patients with IgAN.
The primary endpoint was met with a statistically significant dose response effect on reduction in proteinuria with iptacopanas compared to placebo at 90-day regimen. Iptacopan also showed a trend toward stabilization of kidney function.
It is significant to note here that IgAN currently does not have approved treatments.
Hence, the efficacy data, seen after 90 days of treatment, along with the safety profile raises hope that inhibition of the alternative complement pathway with iptacopan could be an effective way to delay the IgAN disease progression. This, in turn, also increases the probability of a likely approval if the subsequent data is found favorable.
A phase III study APPLAUSE is already underway.
Iptacopan is the most advanced asset in Novartis’ nephrology pipeline and targets the alternative complement pathway, a key driver of complement-driven renal diseases (CDRDs), which include IgAN and C3 glomerulopathy (C3G), and the blood disorder paroxysmal nocturnal hemoglobinuria (PNH).
The candidate received an orphan drug designation in Europe for IgAN, apart from orphan drug designations from the FDA and EMA for C3G and PNH, an FDA Breakthrough Therapy Designation for PNH and an EMA PRIME designation for C3G.
The company also announced results from the phase III RATIONALE 302 study at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. Results showed that the investigational anti-PD-1 immune checkpoint inhibitor tislelizumab improved overall survival (OS) compared to chemotherapy.
Shares of Novartis have lost 4.9% so far this year against the
industry’s growth of 5.5%.
Image Source: Zacks Investment Research
In April 2021,
Calliditas Therapeutics AB ( CALT Quick Quote CALT - Free Report) announced that the FDA accepted its submission and granted a Priority Review to the New Drug Application (NDA) for Nefecon, a down regulator of IgA1 for the treatment of IgA nephropathy (IgAN.) Omeros ( OMER Quick Quote OMER - Free Report) is also evaluating narsoplimab for IgAN.
Novartis currently carries a Zacks Rank #4 (Sell).
A better-ranked stock in the large cap pharma space is
Bayer AG ( BAYRY Quick Quote BAYRY - Free Report) , which currently carries a Zacks Rank #2 (Buy). You can see . the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here
Bayer’s earnings estimates have been revised 4% upward for 2021 and 5.8% for 2022 over the past 30 days.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>